Queensenta (semaglutide) [Ozempic]

Instructions for Queensenta (semaglutide) [Ozempic]

Semaglutide is a hypoglycemic drug classified as a glucagon-like peptide-1 receptor agonist (GIP-1). It is an analog of native GIP-1, with a high degree of homology to the human variant, which determines its ability to effectively activate GIP-1 receptors located in various organs such as the pancreas and brain.

Pharmacologic effects of semaglutide include Ozempic

Decreased blood glucose:
Semaglutide stimulates insulin secretion in response to increased glycemia and inhibits glucagon production, which helps lower blood sugar levels.
It also slows gastric emptying, which helps reduce sudden swings in glucose levels after meals.
Control of appetite and weight loss:

Semaglutide reduces overall food intake by improving signals of satiety and by reducing cravings.
Influencing brain neural networks responsible for controlling hunger and satiety can improve food regulation and reduce insulin resistance.

Cardiovascular effects Ozempic:

Activation of GIP-1 receptors can also have a positive effect on the cardiovascular system, including lowering blood pressure and improving the lipid profile.

Anti-inflammatory effect:
Studies have shown that semaglutide has an anti-inflammatory effect and can reduce the inflammation associated with atherosclerosis.

Prevention of atherosclerosis Queensenta:

In experimental studies in animals, semaglutide demonstrates the ability to inhibit the development of atherosclerotic plaques and reduce inflammatory processes in vessels.

Due to its long-term action (half-life of about one week), semaglutide can be used subcutaneously once a week, which is convenient for patients. Mechanisms of its action also include enzyme stability, making it an effective tool for controlling diabetes and comorbid conditions.

Indications for use Ozempic:

It is reserved for people with type 2 diabetes who are following a diet and exercise. It is used to improve blood glucose control, both alone and in combination with other oral hypoglycemics (OHCG).

The drug can be used in combination with metformin, sulfonylurea derivatives or thiazolidinedione. It can also be used in combination with insulin for patients who have not achieved adequate glucose control with previous therapy with this drug and metformin.

Method of administration and dosage Queensenta

The drug is administered subcutaneously in the abdomen, thigh or shoulder. It can be used at any time, without regard to food intake. If necessary, the day of the injection can be changed, but it is important to observe an interval of at least 3 days (72 hours) between two injections.
The initial dose is 0.25 mg, administered once a week. After 4 weeks, the dose should be increased to 0.5 mg, also administered once a week.